Abstract

Although the emergence of the plasmid-mediated colistin resistance gene, mcr-1, caused global concern, little is known about its clinical implications and transmission characteristics over time. We aimed to investigate the clinical relevance of infection with mcr-1-positive Escherichia coli isolates and to investigate long-term plasmid dynamics. We did a multicentre case-control study and molecular epidemiological survey of mcr-1-positive E coli infections. E coli isolates from four hospitals in China in 2008 to 2017 were collected and screened for mcr-1 by PCR and Sanger sequencing. Patients with mcr-1-positive E coli infections and matched controls with mcr-1-negative E coli infections were included in a 1:4 ratio, considering age, sex, living environment, comorbidities, antimicrobials used, and clinical sample type as potential risk factors in a regression model. 28-day mortality was also observed. The genomes of all mcr-1-positive E coli were sequenced to explore their genetic background and map IS Apl1 elements. Plasmids carrying mcr-1 were characterised by their resistance profile and incompatibility group. 29 100 isolates were collected across all hospitals and during the study period, 300 (1·03%) of which were mcr-1-positive E coli. The overall proportion of mcr-1-positive isolates significantly increased from 0·42% (1 of 240) in 2008 to 1·39% (66 of 4748; p<0·0001) in 2017. Factors related to health-care contact, including receiving cancer care, indwelling central venous catheter, and hospitalisation in the past 3 months, and some sample types (pus secretion and sputum) were significantly associated with mcr-1-positive E coli infection. 28-day mortality was low in both mcr-1-positive (11 [4·4%] of 248 patients) and mcr-1-negative (39 [3·8%] of 1030 patients) groups and did not significantly differ. Although the genetic background of mcr-1-positive E coli was diverse, most of the mcr-1-encoding plasmids occurred in three dominant Inc groups (IncX4, IncI2, and IncHI2). Only the large IncHI2 plasmids conferred multiple resistances and probably integrated with other resistance plasmids. In 205 (68%) of 300 mcr-1-positive E coli isolates, mcr-1 genes lost their capacity for mobilisation because of loss of flanking IS Apl1 elements. The prevalence of mcr-1-positive E coli infection among patients increased over the study period, although it remained low. Health-care contact was the most probable risk factor. Plasmids are likely to have played a critical role in mcr-1 transmission, rather than clone dissemination and lateral transfer of IS Apl1. Our findings underscore the importance of continued surveillance of E coli strains positive for mcr-1 and potentially other resistance-associated genes, particularly in hospital settings. National Natural Science Foundation of China.

Highlights

  • Infections caused by multidrug-resistant Gram-negative bacteria are global threats to human health.[1]

  • We aimed to evaluate the threats of mcr-1-positive E coli infections in humans and provide evidence concerning prevalence, risk factors, and effect on mortality, the mobility of the mcr-1 gene, and multidrug resistance mediated by plasmids

  • Implications of all the available evidence Our study shows that the prevalence of mcr-1-positive E coli infection in China remains low, and it contributed relatively little to patient mortality

Read more

Summary

Introduction

Infections caused by multidrug-resistant Gram-negative bacteria are global threats to human health.[1]. A cationic polypeptide belonging to the polymyxin family, has been introduced into clinical practice as a last resort therapeutic option, mainly for infections with Enterobacterales producing carbapenem-hydrolysing β-lactamase.[2] In China, colistin has been overused in animals for a long time and was approved for use as an oral drug in humans by the Chinese Food and Drug Administration ( the National Medical Products Administration) in June, 2015. It has been used extensively for carbapenem-resistant Enterobacterales infection as a parenteral drug since April, 2018. Colistin resistance has emerged and was initially reported to be chromosomally mediated through the modulation of twocomponent regulatory systems, leading to the modification of lipid A.3 Later, a plasmid-mediated colistin resistance gene, mcr-1, which encodes a phospho­ethanolamine transferase, was identified.[4] mcr-1 is mainly located on plasmids[5,6] and often forms part of a composite transposon, Tn6330 (ISApl1-mcr-1-pap2-ISApl1), which is responsible for its mobilisation.[7,8,9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call